Steven G. Anderson, President, Founder & CEO / Source: RRY Publications
Medafor, the manufacturer of a powder hemostat, metaphorically dumped it on CEO Steven G. Anderson’s head with last week’s strong rejection of CryoLife’s hostile takeover bid. Fully 99% of Medafor’s shareholders have ignored CryoLife’s appeals. Read more.
Leonardo Da Vinci, Vitruvian Man
Recent high profile failures of medical technology start-up firms drives home some important lessons. Namely the key to successful medical technology investing is NOT in the technology it is in the cheap SOB running the company.
Image source: RRY Publications
Last week, CryoLife slammed Medafor against the boards by mailing an open letter to Medafor’s shareholders urging them to override management’s decision NOT to sell to CryoLife. The gloves are off and CryoLife’s Steve Anderson is back in his customary Bad Boy role.
Photo source: RRY Publications
If 2009 was the year of recovery, will 2010 be the year of decline? What should manufacturers, surgeons, and providers expect in the New Year? On balance, we think there is more cause for anxiety than optimism. But then, like most prognosticators, we’ve been wrong before. Check out our analysis here.
John Brown
John Brown, former head of Stryker, had heavy responsibilities from the time he could hold a garden hoe. From rural Tennessee to the “big city,” Brown became an icon, and led Stryker to consistent 20% earnings.
Fire Fighting / Wikimedia Commons
NuVasive fights back and says there are no coding or reimbursement issues for its XLIF procedure. But questions about future reimbursements and a slew of short sales have cut the company’s market cap by almost $600 million in the last two months. Read what company CEO Lukianov told analysts on November 30.
Tightrope Walking/Wikimedia Commons
The spine product market as a whole continues to see revenue growth at a steady rate. Smaller companies, however, face a capital crunch and possible acquisition. Which companies will come out on top? Read it here.